Related Experiment Video

Updated: Aug 5, 2025

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.2K

Cyclocreatine Phosphate: A Novel Bioenergetic/Anti-Inflammatory Drug That Resuscitates Poorly Functioning Hearts and

Salwa A Elgebaly1,2, Charles Van Buren3, Robert Todd4

  • 1Research & Development, Nour Heart, Inc., Vienna, VA 22180, USA.

Pharmaceuticals (Basel, Switzerland)
|March 29, 2023
PubMed

Insights

Cyclocreatine phosphate (CCrP) shows promise in preventing and treating heart failure (HF) caused by myocardial injury. This bioenergetic compound preserves cardiac function and reduces inflammation in rat models, suggesting potential clinical applications.

Area of Science:

  • Cardiology
  • Biochemistry
  • Pharmacology

Background:

  • Myocardial injury leads to adenosine triphosphate (ATP) depletion, contributing to heart failure (HF).
  • Cyclocreatine phosphate (CCrP) has demonstrated the ability to preserve myocardial ATP during ischemia and maintain cardiac function in animal models.

Purpose of the Study:

  • To evaluate the prophylactic and therapeutic efficacy of CCrP in preventing HF secondary to ischemic injury using an isoproterenol (ISO)-induced rat model.

Main Methods:

  • Thirty-nine rats were divided into control and ISO groups, with CCrP administered prophylactically or therapeutically.
  • Measurements included cardiac enzymes, ECG, cardiac remodeling markers, ejection fraction (EF%), and physical activity.

Main Results:

  • CCrP administration, both prophylactic and therapeutic, protected against ISO-induced cardiac injury, evidenced by reduced CK-MB elevation and ECG/ST changes.
  • Prophylactic CCrP decreased heart weight, hs-TnI, TNF-α, TGF-β, and caspase-3, while increasing EF%, eNOS, and connexin-43.
  • Therapeutic CCrP normalized EF%, physical activity, and serum levels of hs-TnI and BNP, with reduced cardiac remodeling.

Conclusions:

  • CCrP acts as a bioenergetic and anti-inflammatory agent, showing significant promise as a safe therapeutic option for myocardial ischemic sequelae and HF.
  • CCrP's ability to salvage poorly functioning hearts supports its potential for clinical application.

Keywords:
adenosine triphosphateanti-inflammatorybioenergeticcyclocreatine phosphateheart failuremyocardial ischemia

More Related Videos

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle09:40

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle

Published on: January 19, 2017

11.8K
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.3K

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
659
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
14
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
52
Muscle Recovery and Fatigue01:24

Muscle Recovery and Fatigue

Muscle fatigue refers to the decline in a muscle's ability to maintain the force of contraction after prolonged activity. It primarily stems from changes within muscle fibers. Even before experiencing muscle fatigue, one may feel tired and have the urge to stop the activity. This response, known as central fatigue, occurs due to changes in the central nervous system, namely the brain and spinal cord. While there is no single mechanism that induces fatigue, it may serve as a protective...
2.2K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
20
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
18